Baird Financial Group, Inc. Nektar Therapeutics Transaction History

Baird Financial Group, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$15.87 - $23.12 $3.52 Million - $5.13 Million	-221,777 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$16.91 - $36.27 $3.75 Million - $8.04 Million	221,777 New	221,777 $4.04 Million
Q2 2019 Aug 14, 2019	SELL	$31.0 - $36.3 $3.09 Million - $3.62 Million	-99,788 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$31.58 - $46.35 $3.15 Million - $4.63 Million	99,788 New	99,788 $3.37 Million
Q4 2018 Feb 14, 2019	SELL	$30.43 - $56.65 $467,739 - $870,767	-15,371 Closed	0 $0

Q3 2018 Nov 13, 2018	BUY	$46.46 - $68.49 $3,019 - $4,451	65 Added 0.42%	15,371 $873,000
Q2 2018 Aug 13, 2018	BUY	$46.25 - $104.45 $262,283 - $592,335	5,671 Added 58.86%	15,306 $747,000
Q1 2018 May 14, 2018	BUY	$57.4 - $108.44 $553,049 - $1.04 Million	9,635 New	9,635 $1.02 Million

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $219M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Baird Financial Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Baird Financial Group, Inc. with notifications on news.